[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 721
Citations 0
Lab Reports
January 2, 2013

Cancer Drug Resistance

JAMA. 2013;309(1):20. doi:10.1001/jama.2012.173440

Cancer cells may develop drug resistance by suppressing expression of the gene MED12, reports an international group of researchers (Huang S et al. Cell. 2012;151[5]:937-950).

The researchers identified MED12 when looking for genes that, when suppressed, confer resistance to the targeted therapy crizotinib in non–small cell lung cancer cells. They then found that MED12 inhibition resulted in resistance not only to crizotinib, but also to other targeted drugs and chemotherapy used to treat colon cancer, melanoma, and liver cancer. Previous research has revealed mutations in MED12 in various types of cancer cells.